Editas Medicine names Erick Lucera as CFO, replacing Michelle Robertson

Editas Medicine, Inc.

Erick Lucera appointed EVP and CFO effective May 17, 2023, succeeding Michelle Robertson who stepped down May 16.
Lucera previously CFO at AVEO Pharma; receives $470k base salary, 45% target bonus, and equity grants.
Equity includes option for 155,800 shares, RSU for 77,900 shares, and performance-based PSU for 77,900 shares.
Robertson will transition through Aug 16, 2023, receiving 12 months base salary and COBRA contributions.
Robertson's vested stock option exercise period extended to Aug 16, 2024; release agreement required.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erick J. Lucera

Executive Vice President and Chief Financial Officer

EDIT · Editas Medicine, Inc.

Effective: 2023-05-17
Filed: May 17, 2023, 7:59 PM ET

On May 16, 2023, Editas Medicine, Inc. (the “Company”) appointed Erick J. Lucera as Executive Vice President and Chief Financial Officer of the Company, effective May 17, 2023, succeeding Michelle Robertson as Executive Vice President and Chief Financial Officer of the Company

Departed

Michelle Robertson

Executive Vice President and Chief Financial Officer

EDIT · Editas Medicine, Inc.

Effective: 2023-05-16
Successor: Erick J. Lucera
Filed: May 17, 2023, 7:59 PM ET

who stepped down as the Company’s Chief Financial Officer effective May 16, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erick J. Lucera was appointed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On May 16, 2023, Editas Medicine, Inc. (the “Company”) appointed Erick J. Lucera as Executive Vice President and Chief Financial Officer of the Company, effective May 17, 2023, succeeding Michelle Robertson as Executive Vice President and Chief Financial Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michelle Robertson departed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..

Action: stepped down
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

who stepped down as the Company’s Chief Financial Officer effective May 16, 2023

View on SEC.gov

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-010139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.